Another day and nothing to talk about except more selling. There is really nothing more to say at this point that has not already been said. There is a significant correction in the growth sector of the market and funds are hitting the sell button every day and it will continue despite the fundamentals of […]
April 14 Biotech Update-
It was a really slow day on the news front, which could simply relate to the start of a pre-holiday week. I did not think it would extend all the way to today but so far nothing major happening in the sector. I will touch on a couple of ideas but will keep this short […]
IBB – Biotech Sector in The Despondency Point
iShares Nasdaq Biotechnology (IBB) – Nasdaq The best indicators for our biotech portfolios are the biotechnology indices IBB, NBI, XBI or XLV. We will maintain our focus on the IBB as the biotech barometer, which has suffered lately from an over exposure. It has been mentioned nonstop on any financial TV programs or investors reports, trying […]
Catalyst Watch – Vol. 2, Edition 11 (4/11/14)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted), are subject to potential future, pre-catalyst revision and are not intended as investment recommendations. Please read our Disclaimer: (1) Catalyst Watch List – Update: CYTK: […]
April 11 Biotech Update- The Beating Continues
Well, there is not much to say about the market and sector other than selling is in vogue and there does not seem to be a clear catalyst that could change the tone of the market. I would also remind you that the apparent catalyst of this negative turn (pricing letter from Congress to GILD) […]
Celgene Markman Hearing Documents
Celgene Reply Markman Decl ISO Celgene Markman Reply-1 CELG brief Natco got RLI illegally blocks access to employee who got RLI fro Natco
April 9 Biotech Update
As we have been apt to do, this morning was relatively strong but we need to see how this holds up throughout the day. If we are to be optimistic, then having a rally so close to the negative pricing headlines is good as was the decent performance of a number of small caps yesterday. […]
April 8 Biotech Update- Revenge of the Pricing Questions
While I was expecting to talk a little about AGIO today, I want to go back to the macro sector sentiment as the proverbial hits keep on coming with ESRX making more noise about Sovaldi prices. In general, ESRX is arguing that GILD is going to bankrupt the entire healthcare system and that they will […]
April 7 Biotech Update- An Active AACR
So a lot to talk about and I will briefly touch on a lot and then expand later this week as I doubt many days will be a busy as today in term of news. The sector had a good morning but we have seen this before and at this point it will not be […]
Pfizer – Technical points to watch
Pfizer Inc. (PFE) -NYSE A long awaited date from Pfizer revealed on Sunday April 04, 2014 at the AACR-2014. Pfizer announced detailed results from the PALOMA-1 study, a randomized Phase 2 study of palbociclib in combination with letrozole. PALOMA-1 achieved its primary endpoint by significantly prolonging progression-free survival (PFS) compared with letrozole alone in post-menopausal women with […]
Catalyst Watch – Vol. 2, Edition 10 (4/4/14)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted), are subject to potential future, pre-catalyst revision and are not intended as investment recommendations. Please read our Disclaimer: (1) Catalyst Watch List – Update: CYTK: […]
April 4 Biotech Update
As often happens when you have small children the best laid plans are often disrupted. So I am taking care of a child with a suspected strep throat infection (the irony is certainly not lost on me given how much time I spend researching antibiotics and the companies that are developing new treatments) and this […]
April 2nd Biotech Update
The sector was a little manic today in that the large caps continue to find a good bid but as you move down the market cap food chain the price action is more mixed. This makes perfect sense as investors are slowly coming back into the sector and are going after value and the security […]
April 1 Biotech Update- Trying Not to be Fooled by the Rally
So it appears that window dressing is over and people are now willing to buy small cap biotechs but as with every other morning we need to see if this interest continues throughout the day. I am not completely convinced that the small cap selling was entirely window dressing but there is something to be […]
March 31 Biotech Update- Is this the Bounce We are Looking For?
So this seems to be the rally we were looking for but that is assuming it does not fade in the afternoon like every other recent rally attempt. So far the rally is a little more broad based and stronger but we have seen this story before. That being said even if this is the […]
Catalyst Watch – Vol. 2, Edition 9 (3/28/14)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted), are subject to potential future, pre-catalyst revision and are not intended as investment recommendations. Please read our Disclaimer: (1) Catalyst Watch List – Update: CYTK: […]
A Follow Up
Just a really quick update. I had a good email exchange with one of the lead ACLF trial investigators and he basically confirmed what CNAT noted in their CC. The exclusion/inclusion criteria were so restrictive that it was virtually impossible for anyone to qualify. The investigator was confident that the issues were corrected with the […]
March 28 Biotech Update- Treading Water Can Be Dangerous
So today was another mixed day for biotechs but the large caps still are above the recent lows and even the “bad” news of the sovaldi new scripts being down for a week was not enough to push GILD to new lows or even really have much pin action across the sector. So all of […]
March 26- Biotechs are Not Dead Yet
This is a better day but sellers still seem there but buying seems more concerted today. It appears that yesterday was the buyers dipping their toes in the water to make sure the coast was clear and today they seemed much more willing to put cash to work. As we saw with yesterday, however, the […]
INSM – Quick take on Insmed
Insmed (NASDAQ: INSM) is expected to report top-line data from a Phase II trial of Arikace in non-tuberculosis mycobacteria (NTM) infection tomorrow morning. This is a double-blind placebo-controlled study that has recruited 90 patients and is comparing the change in semi-quantitative mycobacterial culture density on a seven-point scale from baseline to the end of treatment […]
